



## Curriculum Vitae

### Personal information Caridad Pontes

#### Work experience

---

1. Employer: Corporació Sanitària Parc Taulí
  - Start date: 012011
  - End date: 062016
  - Position: Consultant physician. Responsible for the Clinical Pharmacology Unit.
  - Activities: Member of the Ethics Committee for Clinical Research. Member of the Institutional Committee of Pharmacotherapeutics. Hospital Pharmacovigilance. Methodological support to clinical research projects. Drug utilization studies. Drug selection and drug information.
  - Country: Spain
2. Employer: Servei Català de la Salut
  - Start date: 062016
  - End date:
  - Position: Medicines manager
  - Activities: Catalan Health System, medicines manager since 2020. Formerly in charge of appraisal of therapeutic value, drug positioning and decision on criteria for access to innovative medicines.
  - Country: Spain
3. Employer: Universitat Autònoma de Barcelona
  - Start date: 122010
  - End date:
  - Position: Associate Professor
  - Activities: Department of Pharmacology, Toxicology and Therapeutics. Teaching and coordination of Pharmacology and Clinical Pharmacology at the Teaching Unit Parc Taulí, School of Medicine of Universitat Autònoma de Barcelona.
  - Country: Spain
4. Employer: Palau Pharma S.A.
  - Start date: 122006
  - End date: 122010
  - Position: Head of Clinical Research & Regulatory Affairs
  - Activities: Technical and managerial responsibility on Clinical research and Regulatory Affairs for the company, reporting to the Drug Development and Clinical Research Director. Member of the Management Board. Responsible for planning, design and execution of clinical development plans for new chemical entities, focused on early clinical development from first into man to proof of concept, in the areas of dermatology, gastroenterology, analgesia and respiratory. Responsible for IMPDs, IBs, briefing documents and regulatory interactions with Regulatory Agencies. Responsible person for Eudravigilance and Pharmacovigilance for the company. Responsible for implementation and maintenance of GCP in the newly created department, including set\_up and management of SOPs. Collaboration with the Business Development Department for technical support to the the licensing out of products, to technical follow\_up of licensed products, and to assess licensing opportunities, including due diligences.
  - Country: Spain
5. Employer: Procter & Gamble Pharmaceuticals
  - Start date: 052004
  - End date: 112006
  - Position: Senior Scientist. Pharmacovigilance, Pharmacoepidemiology & Pharmacoconomics.
  - Activities: Qualified Person for PV in Spain. Pharmacovigilance contact person for the Spanish Medicines Agency. Review of monthly symptom frequency report, SAE listings and compliance reports. Review of PSURs for local products. Pharmacovigilance Physician: medical support to the European Qualified Person for pharmacovigilance. Assessment of medical significance of suspected adverse reactions. Medical evaluation of safety data, individual and aggregate patient safety data in reports and summaries for clinical studies and marketed products. Deputy Qualified Person for Pharmacovigilance in Europe: medical support to a non\_medical European Qualified Person, and back\_up QP\_PV role. Overview of PV systems and follow\_up of system audits. Review of monthly symptom frequency report, SAE listings and compliance reports for local affiliates. Review of PSURs for European local and global products. Participation in PV Safety Analysis Group meetings. Ongoing review of all SAE reports. Pharmacoepidemiology responsible for Europe: Pharmacoepidemiology activities for marketed products and support for products in Phase II, III, and IV projects, including input to Risk Management Plans. Analyses of poblational Health Care Databases (GPRD). Other epidemiologic initiatives across P&G as needed.
  - Country: Spain
6. Employer: Laboratorios Vita S.A.
  - Start date: 012002
  - End date: 052004
  - Position: Head of Clinical Pharmacology
  - Activities: Technical support and management of the Section (1 MD clinical monitor, 1 MD safety officer for investigational products, 1 CRA and 1 administrative). SOP update and creation; training and follow\_up of quality control procedures. Planning, design and conduction of clinical development plans and clinical trials from phase I to III\_b with innovative products of the company in the areas of cardiovascular, analgesia and metabolism, in diverse European countries and the USA. Bioequivalence studies with generic products. Supervision of data management and statistics. Integrated safety data analyses for investigational products. Technical support to the Medical Department for the design, conduction and analysis of phase IV studies, and to the Post\_Marketing Safety Officer for the assessment of SAE, elaboration of PSUR

and reporting of phase IV data. Clinical support to Regulatory Affairs during local and EU Marketing Authorisation Applications by Mutual Recognition Procedure; also for the elaboration and requests of PEI (Investigational New Product qualification) to the Spanish Agency of Medicines and IND to the FDA. Collaboration with the Medical and Marketing Departments: communication of clinical results to opinion leaders and congresses; technical support for the launch of an antihypertensive product. Support to the Business Development and Licensing Department: for the technical evaluation of new licenses "in" and presentation of the medical aspects of licenses "out".

- Country: Spain
7. Employer: J Uriach & Cia S.A.
- Start date: 091996
  - End date: 122001
  - Position: Head of the Clinical Pharmacology Department, R&D Area
  - Activities: Exploratory development of new products (anti\_inflammatory drug for IBD, COX\_2 inhibitor, systemic antifungal drug). Responsible for planning and conduction of clinical trials from phase I to early phase II with these products. Responsible scientist consultant for a NCE for IBD within R&D: technical co\_ordination of a multidisciplinary team for project planning; identification and co\_ordination of a Scientific Advisory Panel; technical communication of the project. Previously: Project leader for the completion of the development of a new vaginal antifungal drug already in clinical phase II until launch: analysis of the technical and commercial viability of the project. Definition of the project specifications, planning of the execution phase and co\_ordination of the project team; detection and correction of problems, and progress reporting to management. Previously: Monitoring and design of clinical trials from phases I to III in the areas of dermatology and gynecology (topical antifungal drug), cardiovascular (NCE for hypertension; antiaggregant drug for AMI and stroke prevention) and allergy (antihistaminic drug). Responsible for study planning, protocol writing, CRAs support and financial follow\_up of the project. ICH report writing; communication and publication of results. Expert reporting. Special background in data management and statistics; collaboration in the implantation of the ClinTrial application for data management and in the process of standardisation of data modules and statistical analysis in clinical trials. Clinical support to Regulatory Affairs during local Marketing Authorisation Applications and during MRP for an antihistaminic product for allergic rhinitis and a topical antifungal drug for dermatomycoses. Request of Scientific advice to the Spanish Medicines Agency for new indications for a topical antifungal product.
  - Country: Spain

## Education and training

1. Subject: Department of Pharmacology, Therapeutics and Toxicology. Universitat Autònoma de Barcelona
  - Start date: 121999
  - End date: 102004
  - Qualification: PhD in Medicine and Surgery
  - Organisation: Doctoral thesis: 'Risk of colorectal cancer: relationship with previous exposure to drugs. Case\_Control study.' Department of Epidemiology and Public Health. Institut Català d'Oncologia, Hospital Duran i Reynals // Department of Pharmacology, Therapeutics and Toxicology. Universitat Autònoma de Barcelona Defended in October 2004 : "Excel.lent Cum Laude."
  - Country: Spain
2. Subject: Universitat Autònoma de Barcelona
  - Start date: 091984
  - End date: 061990
  - Qualification: MD
  - Organisation: Degree in Medicine and Surgery
  - Country: Spain
3. Subject: Ministerio de Sanidad y Consumo
  - Start date: 011991
  - End date: 121994
  - Qualification: Medical specialist in Clinical Pharmacology
  - Organisation: Medical internship at Hospital Universitari Vall d'Hebron
  - Country: Spain

## Additional information

### Publications

1: Brunet E, Vela E, Melcarne L, Llovet LP, Puy A, Clèries M, Pontes C, García\_Iglesias P, Villòria A, Kaplan GG, Calvet X. Heterogeneity in pharmacological treatment and outcomes in Crohn's disease patients in Catalonia: a population\_based observational study. *Ann Med.* 2022 Dec;54(1):1255\_1264. doi: 10.1080/07853890.2022.2069851. PMID: 35499519; PMCID: PMC9126589. 2: Selke Krulichová I, Selke GW, Bennis M, Hajiebrahimi M, Nyberg F, Fürst J, Garuolienė K, Poluzzi E, Slabý J, Yahni CZ, Altini M, Fantini MP, Kočí V, McTaggart S, Pontes C, Reno C, Rosa S, Pedrola MT, Udovič M, Wettermark B. Comparison of drug prescribing before and during the COVID\_19 pandemic: A cross\_national European study. *Pharmacoepidemiol Drug Saf.* 2022 Oct;31(10):1046\_1055. doi: 10.1002/pds.5509. Epub 2022 Jul 18. PMID: 35791700; PMCID: PMC9350215. 3: Laso\_Morales MJ, Vives R, Bisbe E, García\_Erce JA, Muñoz M, Martínez\_López F, Caro\_Boeris F, Pontes\_García C. Single\_dose intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of post\_operative anaemia in colorectal cancer patients: a randomised controlled trial. *Blood Transfus.* 2022 Jul;20(4):310\_318. doi: 10.2450/2021.0157\_21. Epub 2021 Oct 15. PMID: 34694223; PMCID: PMC9256505. 4: Fradera M, Uchi D, Prat O, Morros R, Martín\_Fumadó C, Palao D, Cardoner N, Campillo MT, Pérez\_Solà V, Pontes C. Can routine Primary Care Records Help in Detecting Suicide Risk? A Population\_Based Case\_Control Study in Barcelona. *Arch Suicide Res.* 2022 Jul\_Sep;26(3):1395\_1409. doi: 10.1080/13811118.2021.1911894. Epub 2021 Apr 24. PMID: 33896400. 5: Pisana A, Wettermark B, Kurdi A, Tubic B, Pontes C, Zara C, Van Ganse E, Petrova G, Mardare I, Fürst J, Roig\_Izquierdo M, Melien Ø, Bonanno PV, Banzi R, Marković\_Peković V, Mitkova Z, Godman B. Challenges and Opportunities With Routinely Collected Data on the Utilization of Cancer Medicines. Perspectives From Health Authority Personnel Across 18 European Countries. *Front Pharmacol.* 2022 Jun 16;13:873556. doi: 10.3389/fphar.2022.873556. PMID: 35865969; PMCID: PMC9295616. 6: Solís\_Díez G, Turu\_Pedrola M, Roig\_Izquierdo M, Zara C, Vallano A, Pontes C. Dealing With Immunoglobulin Shortages: A Rationalization Plan From Evidence\_Based and Data Collection. *Front Public Health.* 2022 May 19;10:893770. doi: 10.3389/fpubh.2022.893770. PMID: 35664094; PMCID: PMC9160570. 7: Gasol M, Paco N, Guarga L, Bosch JA, Pontes C, Obach M. Early Access to Medicines: Use of Multicriteria Decision Analysis (MCDA) as a Decision Tool in Catalonia (Spain). *J Clin Med.* 2022 Mar 1;11(5):1353. doi: 10.3390/jcm11051353. PMID: 35268443; PMCID: PMC8910942. 8: Godman B, Wladysiuk M, McTaggart S, Kurdi A, Allocati E, Jakovljevic M, Kalemeera F, Hoxha I, Nachtnebel A, Sauermann R, Hinteregger M, Marković\_Peković V, Tubic B, Petrova G, Tachkov K, Slabý J, Nejezchlebova R, Krulichová IS, Laius O, Selke G, Langner I, Harsanyi A, Inotai A, Jakupi A, Henkuzens S, Garuolienė K, Gulbinović J, Bonanno PV, Rutkowski J, Ingeberg S, Melien Ø, Mardare I, Fürst J, MacBride\_Stewart S, Holmes C, Pontes C, Zara C, Pedrola MT, Hoffmann M, Kourafalos V, Pisana A, Banzi R, Campbell S, Wettermark B. Utilisation Trend of Long\_Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications. *Biomed Res Int.* 2021 Oct 11;2021:9996193. doi: 10.1155/2021/9996193. PMID: 34676266; PMCID: PMC8526244. 9: Elvira D, Obach M, Pontes C. Description of the use of multicriteria to support pricing and reimbursement decisions by European health technology assessment bodies. *BMC Health Serv Res.* 2021

Aug 14;21(1):814. doi: 10.1186/s12913\_021\_06784\_8. PMID: 34391431; PMCID: PMC8364048. 10: Bakkum MJ, Richir MC, Papaioannidou P, Likić R, Sanz EJ, Christiaens T, Costa JN, Mačulaitis R, Dima L, Coleman J, Tichelaar J, van Agtmael MA; Education Working Group of the European Association for Clinical Pharmacology and Therapeutics (EACPT) and its affiliated Network of Teachers in Pharmacotherapy (NOTIP). EurOP<sup>2</sup>E – the European Open Platform for Prescribing Education, a consensus study among clinical pharmacology and therapeutics teachers. *Eur J Clin Pharmacol*. 2021 Aug;77(8):1209\_1218. doi: 10.1007/s00228\_021\_03101\_4. Epub 2021 Feb 23. PMID: 33624120; PMCID: PMC8275529. 11: Godman B, Hill A, Simoens S, Selke G, Selke Krulichová I, Zampiroli Dias C, Martin AP, Oortwijn W, Timoney A, Gustafsson LL, Voncina L, Kwon HY, Gulbinovic J, Gotham D, Wale J, Cristina Da Silva W, Bochenek T, Allocati E, Kurdi A, Ogunleye OO, Meyer JC, Hoxha I, Malaj A, Hierländer C, Sauermann R, Hamelinck W, Petrova G, Laius O, Langner I, Yfantopoulos J, Joppi R, Jakupi A, Greiciute\_ Kuprijanov I, Vella Bonanno P, Piepenbrink JH, de Valk V, Wladysiuik M, Marković\_ Peković V, Mardare I, Fürst J, Tomek D, Obach Cortadellas M, Zara C, Pontes C, McTaggart S, Laba TL, Melien Ø, Wong\_ Rieger D, Bae S, Hill R. Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. *Expert Rev Pharmacoecon Outcomes Res*. 2021 Aug;21(4):527\_540. doi: 10.1080/14737167.2021.1884546. Epub 2021 Mar 11. PMID: 33535841. 12: Godman B, Haque M, Leong T, Allocati E, Kumar S, Islam S, Charan J, Akter F, Kurdi A, Vassalo C, Bakar MA, Rahim SA, Sultana N, Deeba F, Khan MAH, Alam ABMM, Jahan I, Kamal ZM, Hasin H, Munzur\_ E\_ Murshid, Nahar S, Haque M, Dutta S, Abhayanand JP, Kaur RJ, Rweggera GM, do Nascimento RCRM, Dias Godói IP, Irfan M, Amu AA, Matowa P, Acolatse J, Incoom R, Sefah IA, Acharya J, Opanga S, Njeri LW, Kimonge D, Kwon HY, Bae S, Khuan KKP, Abubakar AR, Sani IH, Khan TA, Hussain S, Saleem Z, Malande OO, Ployoa\_ Were T, Gambogi R, Hernandez Ortiz C, Alutuli L, Kalungia AC, Hoxha I, Marković\_ Peković V, Tubic B, Petrova G, Tachkov K, Laius O, Harsanyi A, Inotai A, Jakupi A, Henkuzens S, Garuoliene K, Gulbinovic J, Wladysiuik M, Rutkowski J, Mardare I, Fürst J, McTaggart S, MacBride\_ Stewart S, Pontes C, Zara C, Tagoe ET, Banzi R, Wale J, Jakovljevic M. The Current Situation Regarding Long\_ Acting Insulin Analogues Including Biosimilars Among African, Asian, European, and South American Countries; Findings and Implications for the Future. *Front Public Health*. 2021 Jun 24;9:671961. doi: 10.3389/fpubh.2021.671961. PMID: 34249838; PMCID: PMC8264781. 13: Vergara M, Miquel M, Vela E, Cleries M, Pontes C, Prat A, Rué M. Use of healthcare resources and drug expenditure before and after treatment of chronic hepatitis C with direct antiviral agents. *J Viral Hepat*. 2021 May;28(5):728\_738. doi: 10.1111/jvh.13479. Epub 2021 Mar 11. PMID: 33555102. 14: Moreno M, Arévalo M, Zamora M, Pontes C, Oliva JC, Gratacós J. Comparison of disease activity in patients with ankylosing spondylitis under TNFi or NSAID treatment, is there any difference? An observational study. *Reumatol Clin (Engl Ed)*. 2021 Apr;17(4):192\_196. English, Spanish. doi: 10.1016/j.reuma.2019.07.005. Epub 2019 Sep 24. PMID: 31558361. 15: Vivanco\_ Hidalgo RM, Molina I, Martínez E, Roman\_ Viñas R, Sánchez\_ Montalvá A, Fibla J, Pontes C, Velasco Muñoz C; Real World Data Working Group. Incidence of COVID\_19 in patients exposed to chloroquine and hydroxychloroquine: results from a population\_ based prospective cohort in Catalonia, Spain, 2020. *Euro Surveill*. 2021 Mar;26(9):2001202. doi: 10.2807/1560\_7917.ES.2021.26.9.2001202. PMID: 33663646; PMCID: PMC7934222. 16: Bakkum MJ, Tichelaar J, Papaioannidou P, Likić R, Sanz Alvarez EJ, Christiaens T, Costa JN, Mačulaitis R, Dima L, Coleman J, Richir MC, van Agtmael MA; Education Working Group of the European Association for Clinical Pharmacology and Therapeutics (EACPT) and its affiliated Network of Teachers in Pharmacotherapy (NOTIP). Harmonizing and improving European education in prescribing: An overview of digital educational resources used in clinical pharmacology and therapeutics. *Br J Clin Pharmacol*. 2021 Mar;87(3):1001\_1011. doi: 10.1111/bcp.14453. Epub 2020 Aug 1. PMID: 32638391; PMCID: PMC9328439. 17: Gorgas MQ, Torres F, Vives R, Lopez\_ Rico I, Capella D, Pontes C. Effects of selective serotonin reuptake inhibitors and other antidepressant drugs on the risk of hip fracture: a case\_ control study in an elderly Mediterranean population. *Eur J Hosp Pharm*. 2021 Jan;28(1):28\_32. doi: 10.1136/ejhp.2019\_001893. Epub 2019 May 20. PMID: 33355280; PMCID: PMC7788197. 18: Brunet E, Vela E, Melcarne L, Clèries M, Pontes C, Llovet LP, García\_ Iglesias P, Gallach M, Villòria A, Vergara M, Calvet X. Time Trends of Crohn's Disease in Catalonia from 2011 to 2017. Increasing Use of Biologics Correlates with a Reduced Need for Surgery. *J Clin Med*. 2020 Sep 8;9(9):2896. doi: 10.3390/jcm9092896. PMID: 32911630; PMCID: PMC7563515. 19: Vinson D, Molet\_ Benhamou L, Degboé Y, den Broeder A, Ibrahim F, Pontes C, Westhovens R, Závada J, Pham T, Barnette T, Constantin A, Ruysen\_ Witrand A. Impact of tapering targeted therapies (bDMARDs or JAKis) on the risk of serious infections and adverse events of special interest in patients with rheumatoid arthritis or spondyloarthritis: a systematic analysis of the literature and meta\_ analysis. *Arthritis Res Ther*. 2020 Apr 29;22(1):97. doi: 10.1186/s13075\_020\_02188\_x. PMID: 32349791; PMCID: PMC7191828. 20: Roig Izquierdo M, Prat Casanovas MA, Gorgas Torner MQ, Pontes García C. Registry of patients and treatments of hospital medicines in Spain: 10 years of clinical data. *Med Clin (Barc)*. 2020 Mar 13;154(5):185\_191. English, Spanish. doi: 10.1016/j.medcli.2019.09.009. Epub 2019 Nov 20. PMID: 31759696. 21: Pontes C, Zara C, Torrent\_ Farnell J, Obach M, Nadal C, Vella\_ Bonanno P, Ermisch M, Simoens S, Haugeen RC, Gulbinovic J, Timoney A, Martin AP, Mueller T, Nachtnebel A, Campbell S, Selke G, Bochenek T, Rothe CC, Mardare I, Bennie M, Fürst J, Malmstrom RE, Godman B. Time to Review Authorisation and Funding for New Cancer Medicines in Europe? Inferences from the Case of Olaratumab. *Appl Health Econ Health Policy*. 2020 Feb;18(1):5\_16. doi: 10.1007/s40258\_019\_00527\_x. PMID: 31696433. 22: Ibáñez\_ Sanz G, Guinó E, Pontes C, Morros R, de la Peña\_ Negro LC, Quijada\_ Manuitt MÁ, Moreno V. Risk of colorectal cancer in users of bisphosphonates: analysis of population\_ based electronic health records. *Eur J Epidemiol*. 2020 Jan;35(1):37\_48. doi: 10.1007/s10654\_019\_00584\_5. Epub 2019 Nov 16. PMID: 31734885. 23: Escamilla Y, Cardesin A, Samara L, López S, Izquierdo A, Fradera M, Vives R, Bernal\_ Sprekelsen M, Pontes C. Randomized clinical trial to compare the efficacy to improve the quality of surgical field of hypotensive anesthesia with clonidine or dexmedetomidine during functional endoscopic sinus surgery. *Eur Arch Otorhinolaryngol*. 2019 Nov;276(11):3095\_3104. doi: 10.1007/s00405\_019\_05575\_6. Epub 2019 Jul 30. PMID: 31363901. 24: Ibáñez\_ Sanz G, Guinó E, Pontes C, Quijada\_ Manuitt MÁ, de la Peña\_ Negro LC, Aragón M, Domínguez M, Rodríguez\_ Alonso L, Blasco A, García\_ Rodríguez A, Morros R, Moreno V. Statin use and the risk of colorectal cancer in a population\_ based electronic health records study. *Sci Rep*. 2019 Sep 19;9(1):13560. doi: 10.1038/s41598\_019\_49877\_5. PMID: 31537841; PMCID: PMC6753123. 25: van der Voort T, Brinkman DJ, Benemei S, Böttiger Y, Chamontin B, Christiaens T, Likić R, Mačulaitis R, Marandi T, Monteiro EC, Papaioannidou P, Pers YM, Pontes C, Raskovic A, Regenthal R, Sanz EJ, Wilson K, Tichelaar J, van Agtmael MA; Working Group Research on CPT Education of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Appropriate antibiotic prescribing among final\_ year medical students in Europe. *Int J Antimicrob Agents*. 2019 Sep;54(3):375\_379. doi: 10.1016/j.ijantimicag.2019.05.008. Epub 2019 May 7. PMID: 31075400. 26: Molina A, Vicente M, Gasol M, Carbonell P, López P, Pontes C. A Drug Utilization Study of Sacubitril/Valsartan in Catalonia. *Rev Esp Cardiol (Engl Ed)*. 2019 Jul;72(7):593\_595. English, Spanish. doi: 10.1016/j.rec.2018.08.004. Epub 2018 Aug 29. PMID: 30172655. 27: Guarga L, Badia X, Obach M, Fontanet M, Prat A, Vallano A, Torrent J, Pontes C. Implementing reflective multicriteria decision analysis (MCDA) to assess orphan drugs value in the Catalan Health Service (CatSalut). *Orphanet J Rare Dis*. 2019 Jun 27;14(1):157. doi: 10.1186/s13023\_019\_1121\_6. PMID: 31248421; PMCID: PMC6598260. 28: Moreno M, Gratacós J, Torrente\_ Segarra V, Sanmartí R, Morlà R, Pontes C, Llop M, Juanola X; REMINEA study Group. Withdrawal of infliximab therapy in ankylosing spondylitis in persistent clinical remission, results from the REMINEA study. *Arthritis Res Ther*. 2019 Apr 5;21(1):88. doi: 10.1186/s13075\_019\_1873\_3. PMID: 30953541; PMCID: PMC6451276. 29: Moreno M, Lisbona MP, Gallardo F, Deza G, Ferran M, Pontes C, Luelmo J, Maymó J, Gratacós J. Ultrasound Assessment of Psoriatic Onychopathy: A Cross\_ sectional Study Comparing Psoriatic Onychopathy with Onychomycosis. *Acta Derm Venereol*. 2019 Feb 1;99(2):164\_169. doi: 10.2340/00015555\_3060. PMID: 30281142. 30: Vives R, Fernandez\_ Galinski D, Gordo F, Izquierdo A, Oliva JC, Colilles C, Pontes C. Effects of bupivacaine or levobupivacaine on cerebral oxygenation during spinal anesthesia in elderly patients undergoing orthopedic surgery for hip fracture: a randomized controlled trial. *BMC Anesthesiol*. 2019 Jan 31;19(1):17. doi: 10.1186/s12871\_019\_0682\_1. PMID: 30704463; PMCID: PMC6357488. 31: Gratacós J, Pontes C, Juanola X, Sanz J, Torres F, Avendaño C, Vallano A, Calvo G, de Miguel E, Sanmartí R; REDES\_ TNF investigators. Non\_ inferiority of dose reduction versus standard dosing of TNF\_ inhibitors in axial spondyloarthritis. *Arthritis Res Ther*. 2019 Jan 8;21(1):11. doi: 10.1186/s13075\_018\_1772\_z. PMID: 30621746; PMCID: PMC6323809. 32: Laso\_ Morales MJ, Vives R, Vallejo\_ Tarrat A, Caló N, Valle\_ Beltran A, Pontes C. Single dose of intravenous ferric carboxymaltose infusion versus multiple fractionated doses of intravenous iron sucrose in the treatment of postoperative anaemia in colorectal cancer patients: study protocol for a randomised controlled trial. *Trials*. 2019 Jan 7;20(1):23. doi: 10.1186/s13063\_018\_3125\_2. PMID: 30616657; PMCID: PMC6323815. 33: Pontes C, Fontanet JM, Vives R, Sancho A, Gómez\_ Valent M, Ríos J, Morros R, Martinalbo J, Posch M, Koch A, Roes K, Oude Rengerink K, Torrent\_ Farnell J, Torres F. Evidence supporting regulatory\_ decision making on orphan medicinal products authorisation in Europe: methodological uncertainties. *Orphanet J Rare Dis*. 2018 Nov

15;13(1):206. doi: 10.1186/s13023\_018\_0926\_z. PMID: 30442155; PMCID: PMC6238348. 34: Mitroiu M, Oude Rengerink K, Pontes C, Sancho A, Vives R, Pesiou S, Fontanet JM, Torres F, Nikolakopoulos S, Pateras K, Rosenkranz G, Posch M, Urach S, Ristl R, Koch A, Loukia S, van der Lee JH, Roes KCB. Applicability and added value of novel methods to improve drug development in rare diseases. *Orphanet J Rare Dis.* 2018 Nov 12;13(1):200. doi: 10.1186/s13023\_018\_0925\_0. PMID: 30419965; PMCID: PMC6233569. 35: Brunet E, Roig Ramos C, Vela E, Cléries M, Melcarne L, Villória A, Pontes C, Calvet X. Prevalence, incidence and mortality of inflammatory bowel disease in Catalonia. A population based analysis. *Ann Med.* 2018 Nov;50(7):613-619. doi: 10.1080/07853890.2018.1523550. Epub 2018 Nov 19. PMID: 30247071. 36: Vansen van der Weide MC, Gaasterland CMW, Roes KCB, Pontes C, Vives R, Sancho A, Nikolakopoulos S, Jermseulen E, van der Lee JH. Rare disease registries: potential applications towards impact on development of new drug treatments. *Orphanet J Rare Dis.* 2018 Sep 5;13(1):154. doi: 10.1186/s13023\_018\_0836\_0. PMID: 30185208; PMCID: PMC6126025. 37: Brinkman DJ, Tichelaar J, Mokkink LB, Christiaens T, Likic R, Maciulaitis R, Costa J, Sanz EJ, Maxwell SR, Richir MC, van Agtmael MA; Education Working Group of the European Association for Clinical Pharmacology and Therapeutics (EACPT) and its affiliated Network of Teachers in Pharmacotherapy (NOTIP). Key Learning Outcomes for Clinical Pharmacology and Therapeutics Education in Europe: A Modified Delphi Study. *Clin Pharmacol Ther.* 2018 Aug;104(2):317-325. doi: 10.1002/cpt.962. Epub 2018 Jan 30. PMID: 29205299; PMCID: PMC6099198. 38: Laso Morales MJ, Vives R, Gómez Ramírez S, Pallisera Lloveras A, Pontes C. Intravenous iron administration for post-operative anaemia management after colorectal cancer surgery in clinical practice: a single centre, retrospective study. *Blood Transfus.* 2018 Jul;16(4):338-342. doi: 10.2450/2018.0004\_18. Epub 2018 Mar 5. PMID: 29517968; PMCID: PMC6034767. 39: Tafuri G, Lucas I, Estevão S, Moseley J, d'Andon A, Bruel H, Gajraj E, Garcia S, Hedberg N, Massari M, Molina A, Obach M, Osipenko L, Petavy F, Petchschules M, Pontes C, Russo P, Schiel A, Van de Castele M, Zebedin Brandl EM, Rasi G, Vamvakas S. The impact of parallel regulatory health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations. *Br J Clin Pharmacol.* 2018 May;84(5):1013-1019. doi: 10.1111/bcp.13524. Epub 2018 Mar 5. PMID: 29370449; PMCID: PMC5903262. 40: Puig Comas G, García Peláez M, Gorgas Torner MQ, Pontes García C. Serotonin syndrome during a heat wave. *Emergencias.* 2018 Feb;30(1):62-63. English, Spanish. PMID: 29437313. 41: Pontes C, Marsal JR, Elorza JM, Aragón M, Prieto Alhambra D, Morros R. Analgesic Use and Risk for Acute Coronary Events in Patients With Osteoarthritis: A Population based, Nested Case control Study. *Clin Ther.* 2018 Feb;40(2):270-283. doi: 10.1016/j.clinthera.2017.12.011. Epub 2018 Feb 3. PMID: 29398161. 42: Quijada Manuitt MA, Escamilla Y, Vallano A, Cardesin A, Bernal Sprekelsen M, Pontes C. Use of  $\alpha_2$  Adrenergic Agonists to Improve Surgical Field Visibility in Endoscopy Sinus Surgery: A Systematic Review of Randomised Controlled Trials. *Clin Ther.* 2018 Jan;40(1):136-149.e19. doi: 10.1016/j.clinthera.2017.11.010. PMID: 29268957. 43: Laso Morales M, Jericó C, Gómez Ramírez S, Castellví J, Viso L, Roig Martínez I, Pontes C, Muñoz M. Preoperative management of colorectal cancer induced iron deficiency anemia in clinical practice: data from a large observational cohort. *Transfusion.* 2017 Dec;57(12):3040-3048. doi: 10.1111/trf.14278. Epub 2017 Aug 21. PMID: 28833205. 44: Torres F, Ríos J, Saez Peñataro J, Pontes C. Is Propensity Score Analysis a Valid Surrogate of Randomization for the Avoidance of Allocation Bias? *Semin Liver Dis.* 2017 Aug;37(3):275-286. doi: 10.1055/s\_0037\_1606213. Epub 2017 Aug 28. PMID: 28847037. 45: Brinkman DJ, Tichelaar J, Schutte T, Benemei S, Böttiger Y, Chamontin B, Christiaens T, Likic R, Ma' iulaitis R, Marandi T, Monteiro EC, Papaionnidou P, Pers YM, Pontes C, Raskovic A, Regenthal R, Sanz EJ, Tamba BI, Wilson K, Vries T, Richir MC, Agtmael MV; Working Group Research on CPT Education of the European Association for Clinical Pharmacology and Therapeutics (EACPT). Essential competencies in prescribing: A first european cross sectional study among 895 final year medical students. *Clin Pharmacol Ther.* 2017 Feb;101(2):281-289. doi: 10.1002/cpt.521. Epub 2016 Nov 17. PMID: 27648725; PMCID: PMC5260337. 46: Pontes C. New Methods and Designs of Clinical Trials. *Clin Ther.* 2016 Oct 6;38(10S):e2-e3. doi: 10.1016/j.clinthera.2016.07.018. PMID: 27673628. 47: Serra M, Vives R, Cañellas M, Planell J, Oliva JC, Colilles C, Pontes C. Outpatient multimodal intravenous analgesia in patients undergoing day case surgery: description of a three year experience. *BMC Anesthesiol.* 2016 Sep 13;16:78. doi: 10.1186/s12871\_016\_0246\_6. PMID: 27619387; PMCID: PMC5020512. 48: Ulldemolins M, Martín Loeches I, Llauredó Serra M, Fernández J, Vaquer S, Rodríguez A, Pontes C, Calvo G, Torres A, Soy D. Piperacillin population pharmacokinetics in critically ill patients with multiple organ dysfunction syndrome receiving continuous venovenous haemodiafiltration: effect of type of dialysis membrane on dosing requirements. *J Antimicrob Chemother.* 2016 Jun;71(6):1651-9. doi: 10.1093/jac/dkv503. Epub 2016 Feb 10. PMID: 26869692. 49: Vives R, Pontes C, Sarasa M, Millier A. Safety and Activity of UR\_1505 in Atopic Dermatitis: A Randomized, Double blind Phase II Exploratory Trial. *Clin Ther.* 2015 Sep 1;37(9):1955-65. doi: 10.1016/j.clinthera.2015.06.005. Epub 2015 Jul 7. PMID: 26163200. 50: Ulldemolins M, Soy D, Llauredó Serra M, Vaquer S, Castro P, Rodríguez AH, Pontes C, Calvo G, Torres A, Martín Loeches I. Meropenem population pharmacokinetics in critically ill patients with septic shock and continuous renal replacement therapy: influence of residual diuresis on dose requirements. *Antimicrob Agents Chemother.* 2015 Sep;59(9):5520-8. doi: 10.1128/AAC.00712\_15. Epub 2015 Jun 29. PMID: 26124172; PMCID: PMC4538468. 51: Wilken R, Li CS, Sharon VR, Kim K, Patel FB, Patel F, Maverakis E. Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial. *Trials.* 2015 Aug 22;16:374. doi: 10.1186/s13063\_015\_0879\_7. PMID: 26297574; PMCID: PMC4546316. 52: Pontes C, Gratacós J, Torres F, Avendaño C, Sanz J, Vallano A, Juanola X, de Miguel E, Sanmartí R, Calvo G. Evaluation of dose reduction versus standard dosing for maintenance of remission in patients with spondyloarthritis and clinical remission with anti\_TNF (REDES\_TNF): study protocol for a randomized controlled trial. *Trials.* 2015 Aug 20;16:370. doi: 10.1186/s13063\_015\_0828\_5. PMID: 26289076; PMCID: PMC4546086. 53: Cardesin A, Pontes C, Rosell R, Escamilla Y, Marco J, Escobar MJ, Bernal Sprekelsen M. A randomised double blind clinical trial to compare surgical field bleeding during endoscopic sinus surgery with clonidine based or remifentanyl based hypotensive anaesthesia. *Rhinology.* 2015 Jun;53(2):107-15. doi: 10.4193/Rhino14.185. PMID: 26030032. 54: Pontes C, Vives R, Torres F, Panés J. Safety and activity of dersenazine sodium in patients with mild to moderate active colitis: double blind randomized proof of concept study. *Inflamm Bowel Dis.* 2014 Nov;20(11):2004-12. doi: 10.1097/MIB.000000000000166. PMID: 25192498. 55: Pallero M, Puy C, Güell R, Pontes C, Martí S, Torres F, Antón A, Muñoz X. Ambulatory adaptation to noninvasive ventilation in restrictive pulmonary disease: a randomized trial with cost assessment. *Respir Med.* 2014 Jul;108(7):1014-22. doi: 10.1016/j.rmed.2014.04.016. Epub 2014 May 2. PMID: 24837977. 56: Ulldemolins M, Vaquer S, Llauredó Serra M, Pontes C, Calvo G, Soy D, Martín Loeches I. Beta lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy. *Crit Care.* 2014 Jun 23;18(3):227. doi: 10.1186/cc13938. PMID: 25042938; PMCID: PMC4075152. 57: Cardesin A, Pontes C, Rosell R, Escamilla Y, Marco J, Escobar MJ, Bernal Sprekelsen M. Hypotensive anaesthesia and bleeding during endoscopic sinus surgery: an observational study. *Eur Arch Otorhinolaryngol.* 2014 Jun;271(6):1505-11. doi: 10.1007/s00405\_013\_2700\_0. Epub 2013 Sep 20. PMID: 24052249. 58: Cabré Serres M, Rudi Sola N, Pontes García C, Vergara Gómez M, Parra Uribe I, Gorgas Torner MQ. Abordaje multidisciplinar como modelo de detección y seguimiento de la morbilidad psiquiátrica en pacientes en tratamiento con interferón de la morbilidad psiquiátrica en pacientes en tratamiento con interferón y ribavirina [Multidisciplinary approach as a model for detection and monitoring of psychiatric morbidity in patients treated with interferon and ribavirin]. *Farm Hosp.* 2014 May 1;38(3):162-8. Spanish. doi: 10.7399/fh.2014.38.3.1159. PMID: 24951901. 59: Torres F, Pontes C. Datos ausentes: orden de búsqueda y captura [Missing data: warrant for search and capture]. *Med Clin (Barc).* 2013 Oct 5;141(7):297-9. Spanish. doi: 10.1016/j.medcli.2013.04.001. Epub 2013 May 22. PMID: 23706686. 60: Román J, Planell N, Lozano JJ, Aceituno M, Esteller M, Pontes C, Balsa D, Merlos M, Panés J, Salas A. Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis. *Inflamm Bowel Dis.* 2013 Feb;19(2):221-9. doi: 10.1002/ibd.23020. PMID: 22605655. 61: Salcedo C, Pontes C, Merlos M. Is the H4 receptor a new drug target for allergies and asthma? *Front Biosci (Elite Ed).* 2013 Jan 1;5(1):178-87. doi: 10.2741/e606. PMID: 23276980. 62: Avendaño Solá C, Delgadillo Duarte J, de Abajo FJ, Sanz N; en representación del Grupo de Trabajo de Ensayos Clínicos de la Sociedad Española de Farmacología Clínica. Cambios en la normativa europea de ensayos clínicos (ii): por una regulación proporcionada y adaptada al riesgo [Changes in the European normative of clinical trials (ii): towards a proportional and risk adapted regulation]. *Med Clin (Barc).* 2012 May 12;138(13):574-8. Spanish. doi: 10.1016/j.medcli.2011.12.010. Epub 2012 Mar 6. PMID: 22401737. 63: Avendaño Solá C, Delgadillo Duarte J, Pontes García C, Cabrera García L; Grupo de Trabajo de Ensayos Clínicos de la Sociedad Española de Farmacología Clínica. Cambios en la normativa europea de ensayos clínicos (i): una oportunidad para mejorar los trámites de autorización [Changes in the European normative of clinical trials (i): a chance to improve the paperwork authorization]. *Med Clin (Barc).* 2012 Apr 28;138(11):493-7. Spanish. doi: 10.1016/j.medcli.2011.12.008. Epub 2012 Mar 6. PMID: 22401721. 64: Cooper C, Steinbuch M, Stevenson R, Miday



R, Watts NB. The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK. *Osteoporos Int.* 2010 Apr;21(4):569-77. doi: 10.1007/s00198\_009\_1003\_1. Epub 2009 Jun 23. PMID: 19547906; PMCID: PMC2832873. 65: Torres F, Calvo G, Pontes C. Recomendaciones metodológicas de las agencias reguladoras [Methodological recommendations of the Regulatory Agencies]. *Med Clin (Barc)*. 2005 Dec 1;125 Suppl 1:72\_6. Spanish. doi: 10.1016/s0025\_7753(05)72213\_2. PMID: 16464431. 66: Marín\_Iranzo R, de la Sierra\_Iserte A, Roca\_Cusachs A, Oliván\_Martínez J, Redón\_Mas J, Luque\_Otero M, de la Figuera\_von Wichman M, Pontes\_García C, Delgadillo\_Duarte J; grupo del estudio ENVIDA. Estudio doble ciego de la eficacia y la seguridad de la combinación a dosis fija de 10 mg de enalapril/20 mg de nitrendipino en comparación con el incremento de dosis de amlodipino en pacientes con hipertensión esencial no controlada con 5 mg de amlodipino [Double blind study of the efficacy and safety of the fixed dose combination of enalapril 10 mg/nitrendipine 20 mg versus the increase of amlodipine dose in essential hypertensive patients not controlled with amlodipine 5 mg]. *Rev Clin Esp.* 2005 Sep;205(9):418\_24. Spanish. doi: 10.1157/13079069. PMID: 16194475. 67: Gemignani F, Landi S, Moreno V, Gioia\_Patricola L, Chabrier A, Guino E, Navarro M, Cambray M, Capellà G, Canzian F. Polymorphisms of the dopamine receptor gene DRD2 and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev.* 2005 Jul;14(7):1633\_8. doi: 10.1158/1055\_9965.EPI\_05\_0057. PMID: 16030094. 68: Menéndez M, González S, Blanco I, Guinó E, Peris M, Peinado MA, Capellà G, Moreno V. Colorectal cancer risk and the APC D1822V variant. *Int J Cancer.* 2004 Oct 20;112(1):161\_3. doi: 10.1002/ijc.20361. PMID: 15305389. 69: Cox DG, Pontes C, Guino E, Navarro M, Osorio A, Canzian F, Moreno V; Bellvitge Colorectal Cancer Study Group. Polymorphisms in prostaglandin synthase 2/cyclooxygenase 2 (PTGS2/COX2) and risk of colorectal cancer. *Br J Cancer.* 2004 Jul 19;91(2):339\_43. doi: 10.1038/sj.bjc.6601906. PMID: 15173859; PMCID: PMC2409800. 70: Culebras A, Rotta\_Escalante R, Vila J, Domínguez R, Abiusi G, Famulari A, Rey R, Bauso\_Tosselli L, Gori H, Ferrari J, Reich E; TAPIRSS investigators. Triflusal vs aspirin for prevention of cerebral infarction: a randomized stroke study. *Neurology.* 2004 Apr 13;62(7):1073\_80. doi: 10.1212/01.wnl.0000113757.34662.aa. PMID: 15079004. 71: de la Sierra A, Gil\_Extremera B, Calvo C, Campo C, García\_Puig J, Márquez E, Oliván J, Roca\_Cusachs A, Sanz de Castro S, Pontes C, Delgadillo J. Comparison of the antihypertensive effects of the fixed dose combination enalapril 10 mg/nitrendipine 20 mg vs losartan 50 mg/hydrochlorothiazide 12.5 mg, assessed by 24\_h ambulatory blood pressure monitoring, in essential hypertensive patients. *J Hum Hypertens.* 2004 Mar;18(3):215\_22. doi: 10.1038/sj.jhh.1001655. PMID: 14973517. 72: Landi S, Moreno V, Gioia\_Patricola L, Guino E, Navarro M, de Oca J, Capella G, Canzian F; Bellvitge Colorectal Cancer Study Group. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator\_activated receptor gamma with colorectal cancer. *Cancer Res.* 2003 Jul 1;63(13):3560\_6. PMID: 12839942. 73: Aramendi JI, Mestres CA, Campos V, Martínez\_León J, Pontes C, Muñoz G, Navas JC. Triflusal versus oral anticoagulation for primary prevention of thromboembolism after bioprosthetic valve replacement (TRAC): rationale and design for a prospective, randomized, co\_operative trial. *Interact Cardiovasc Thorac Surg.* 2003 Jun;2(2):170\_4. doi: 10.1016/S1569\_9293(03)00010\_0. PMID: 17670019. 74: Antoñanzas F, Velasco M, Abbas I, Pontes C, Delgadillo J, Terán M. Modelo teórico de análisis coste\_efectividad de la terapia combinada de enalapril\_nitrendipino en el tratamiento de la hipertensión arterial [Theoretical model of a cost\_effectiveness analysis of combined enalapril\_nitrendipine therapy for treating hypertension]. *Aten Primaria.* 2003;31(6):366\_71. Spanish. doi: 10.1016/s0212\_6567(03)70700\_8. PMID: 12716571; PMCID: PMC7681723. 75: Darbà J, Izquierdo I, Pontes C, Navas C, Rovira J. Economic evaluation of triflusal and aspirin in the treatment of acute myocardial infarction. *Pharmacoeconomics.* 2002;20(3):195\_201. doi: 10.2165/00019053\_200220030\_00005. PMID: 11929349. 76: del Palacio A, Sanz F, Sánchez\_Alor G, Garau M, Calvo MT, Boncompte E, Algueró M, Pontes C, Gómez de la Cámara A. Double\_blind randomized dose\_finding study in acute vulvovaginal candidosis. Comparison of flutrimazole site\_release cream (1, 2 and 4%) with placebo site\_release vaginal cream. *Mycoses.* 2000 Oct;43(9\_10):355\_65. doi: 10.1046/j.1439\_0507.2000.00575.x. PMID: 11105539. 77: Maillard MP, Rossat J, Nussberger J, Ramis J, Pontes C, Burnier M, Brunner HR. Pharmacologic profile of UR\_7247, an orally active angiotensin II AT1 receptor antagonist, in healthy volunteers. p6. *J Cardiovasc Pharmacol.* 2000 Mar;35(3):383\_9. doi: 10.1097/00005344\_200003000\_00006. PMID: 10710122. 78: Cruz\_Fernández JM, López\_Bescós L, García\_Dorado D, López García\_Aranda V, Cabadés A, Martín\_Jadraque L, Velasco JA, Castro\_Beiras A, Torres F, Marfil F, Navarro E. Randomized comparative trial of triflusal and aspirin following acute myocardial infarction. *Eur Heart J.* 2000 Mar;21(6):457\_65. doi: 10.1053/euhj.1999.1874. PMID: 10681486. 79: Arnau JM, Vallano A, Artigas R, Vallés JA, Agustí A, Colomé E, Pontes C, Diogene E. La investigación sobre la utilización de medicamentos en atención primaria en revistas nacionales [Research on drug utilization in primary health care in national journals]. *Aten Primaria.* 1991 Dec;8(11):932\_6. Spanish. PMID: 1807427.

## Projects

Competitive funding AICE: AI supported picture analysis in large bowel camera capsule endoscopy. Setting: European Role: collaborating investigator Organization: Universitat Autònoma de Barcelona, Spain Funding: HORIZON\_HLTH\_2021\_DISEASE\_04\_04 Dates: 1/09/22 – 31/08/26 (ongoing) 1. Project: Assessment of the clinical utility of a standardized protocol for dose reduction in patients with axial espondylarthritis in persistent clinical remission during treatment with TNF antagonists: a multicenter open\_label controlled and randomised trial. Setting: National Role: Principal investigator and study coordinator. Organization: FUNDACIO PARC TAULLI. Sabadell, Cataluña, España Funding: MINISTERIO DE SANIDAD Y CONSUMO (Ayudas para el Fomento de la Investigación Clínica Independiente. Cód. según financiadora: EC11\_229. Dates: 01/01/2012 to 01/12/2014 (ongoing) Other institutions: 31 Spanish sites. 2. Project: Advances in Small Trials dEsign for Regulatory Innovation and eXcelence (ASTERIX) Setting: European Union Role: Investigator \_WP5 Organization: Universitat Autònoma de Barcelona. Barcelona, Cataluña, España Funding: FP7\_HEALTH\_2013\_INNOVATION\_1 Dates: 01/10/2013 to 30/09/2017 Other institutions: Academic Medical Center Amsterdam; Medizinische Hochschule Hannover; Medizinische Universitaet Wien; Statisticians in the Pharmaceutical Industry; Universitat Autònoma de Barcelona; Vereniging Samenwerkende Ouder\_en Patiëntenorganisaties betrokken bij Erfelijkheidsvraagstukken; University Medical Center Utrecht \*Project: Study of prognostic biomarkers and predictors of response to antiTNF treatment in patients with axial spondyloarthritis. Setting: Spain Role: Co\_investigator Organization: Hospital de Sabadell \_ Universitat Autònoma de Barcelona Funding: MINISTERIO DE SANIDAD Y CONSUMO (Ayudas para proyectos de investigación en salud de la convocatoria 2013 de la acción estratégica en salud 2014\_2016) \_ funding code: PI13/02680 Period: 01\_01\_2014 to 31\_12\_2016 Other institutions: 31 Spanish sites. 3. Project: Pharmacokinetic and pharmacodynamic study of the most frequently used wide spectrum antibiotics in the intensive care unit (piperacillin/tazobactam, meropenem, ceftriaxone) in patients with septic shock undergoing high flow renal replacement. Setting: National Role: Investigator Organization: FUNDACIO PARC TAULLI, Sabadell, Cataluña, España funding: MINISTERIO DE SANIDAD Y CONSUMO Ciudad: España (Ayudas para el Fomento de la Investigación Clínica Independiente. Cód. según financiadora: EC11\_226) Dates: 01/01/2012 to 01/12/2014 (ongoing) Other institutions: 4 University hospitals. 4. Project: Multicenter prospective clinical trial with random allocation to parallel groups to compare the efficacy of the home based vs hospital based adaptation to non\_invasive domiciliary mechanical ventilation in patients with chronic respiratory insufficiency secondary to neuromuscular diseases or thoracic deformations. setting: National Role: Investigador/a Organization: Hospital Universitario Vall d'Hebron. Barcelona, Cataluña, España Funding: Beca Abelló\_Linde Cód. según financiadora: Beca 2003 Dates: 01/09/2002 to 01/09/2006 Other institutions: 2 University Hospitals.

## Memberships

□ Registered physician (Col·legi Oficial Metges de Barcelona) since June 1990; No 27,246. Member of Independent Ethic's Committee (Comité Ètic de Investigació Clínica de la Corporació Sanitària Parc Taulí) since 01/03/2011 to 28/02/2019. Member of the Council of the European Association of Clinical Pharmacology and Therapeutics since 2005 to currently. Member of EACPT since 1996. □ Member of the Spanish Society of Clinical Pharmacology since 1991; Member of the Executive Committee Oct 2002\_ Oct 2008. □ Member of the Editorial Board of Investigación Clínica y Bioética (ICB), from Oct 2002 to Oct 2008. □ Member of the Scientific\_technical board for the assessment of applications to public grants "Ayudas para el fomento de la investigación clínica independiente", Ministerio de Salud, Política Social e Igualdad – Spanish Government ( 2010 and 2011).

## Other Relevant Information

President of the Catalan Society of Pharmacology (since dec 2019) Direction of PhD projects: Universitat de Barcelona, PhD in Medicine: Alda Cardesin Revilla "Maneuvers aimed at minimizing the bleeding of the surgical field during nasosinusal endoscopic surgery: randomized clinical trial of the use of an adrenergic alpha agonist hypotensive drug." 23/01/2015– Excel·lent Cum Laude. Directors: Caridad Pontes, Manuel\_Bernal\_Sprekelsen. Universitat Autònoma de Barcelona, PhD in Pharmacology: Maria Queral Gorgas Torner "Evaluation of the prevalence of use of drugs in patients who attend a hospital emergency service with fractures due to bone fragility."

02/02/2016– Excel·lent Cum Laude. Directors: Caridad Pontes, Dolors Capellà Hereu, Universitat Autònoma de Barcelona, PhD in Pharmacology: Roser Vives Vilagut "Design of an exploratory development plan for the assessment of the activity of drugs for the treatment of chronic inflammatory dermatological diseases."  
25/11/2016– Excel·lent Cum Laude. Directors: Caridad Pontes Universitat Autònoma de Barcelona, PhD in Pharmacology: Mónica Gómez\_Valent "Proposal for a new classification of orphan and/or rare conditions based on clinical characteristics that determine the applicability of different research methods to their study."  
07/07/2017– Excel·lent Cum Laude Directors: Caridad Pontes Universitat Autònoma de Barcelona, PhD in Pharmacology: Juan Manuel Fontanet Sacristán "Study to characterize the designs of clinical trials conducted with orphan medicinal products."  
14/09/2017 \_ Excel·lent Cum Laude Directors: Caridad Pontes, Josep Torrent Farnell. Universitat Autònoma de Barcelona, PhD in Pharmacology: Arantxa Sancho Lopez "Validation of new designs applied to the study of orphan drugs: clinical and regulatory impact."  
23/11/2018 \_ Excel·lent Cum Laude Directors: Caridad Pontes, Ferran Torres Universitat Autònoma de Barcelona, PhD in Pharmacology: Yolanda Escamilla Carpintero "Selection of the most appropriate alpha 2 agonist as an anesthetic adjuvant in nasosinusal endoscopic surgery: a randomized clinical trial with clonidine versus dexmedetomidine."  
25/10/2018 \_ Excel·lent Cum Laude Directors: Caridad Pontes, Alda Cardesín, Manuel Bernal\_Sprekelsen. Universitat Autònoma de Barcelona, PhD in Pharmacology: Maria Jesús Laso Morales "Ferroterapia endovenosa en la optimización de la hemoglobina en el postoperatorio de cirugía neoplásica colorrectal"  
11/11/2019 \_ Excel·lent \_ Cum Laude Directors: Caridad Pontes, Roser Vives Vilagut Universitat Autònoma de Barcelona, PhD in Pharmacology: Marta Roig Izquierdo. "Obtenció de resultats en salut com a eina de suport a la presa de decisions de gestió del medicament: registre de pacients i tractaments de la medicació hospitalària de dispensació ambulatoria de Catalunya".  
21/12/2020 \_ Excellent \_ cum laude Directors: Caridad Pontes, Alba Prat Casanovas; Maria Queralt Gorgas Torner Universitat Autònoma de Barcelona, PhD in Pharmacology: Marc Fradera Jimenez "Riesgo de suicidio asociado a factores clínicos y farmacológicos: estudio de casos y controles"  
22/01/2021. Excel·lent \_ cum laude Directors: Caridad Pontes, Víctor Pérez Solá Editorial experience \_ Editorial coordinator: Investigación Clínica y Bioética, 01/11/2010 to 01/11/2011 \_ Member of the editorial board: Investigación Clínica y Bioética de 01/11/2002 al 01/11/2011 \_ Peer reviewer: Arzneimittel Forschung / Drug Research ,Archivos de Bronconeumología, Basic & Clinical Pharmacology and Toxicology, Clinical\_Therapeutics, Clinical\_Epidemiology, Heliyon, Journal of Pain Research, Medicina Legal, Therapeutics\_and\_Clinical\_Risk\_Management, Trials. □ Spanish and Catalan: native languages. English: fluent spoken and written.